ZMYM2 has also been implicated in cancer as a fusion protein with the Fibroblast growth factor receptor 1 (FGFR1) in 8p11 myeloproliferative syndrome (EMS), where it constitutes ∼ 50% of all cases of FGFR1-fusion related myeloid/lymphoid neoplasms (89–91). This evidence concerns the gene ZMYM2 and eosinophilia-myalgia syndrome.